Repatha (evolocumab) Letter of Medical Necessity
Repatha (evolocumab) prior authorization requires rigorous documentation of maximally tolerated statin therapy, ezetimibe trial, and residual LDL-C above target. Statin intolerance claims require specific rechallenge documentation.
FDA-Approved Indications
- ● primary hyperlipidemia (heterozygous FH or clinical ASCVD)
- ● homozygous familial hypercholesterolemia
- ● cardiovascular risk reduction in established ASCVD
Why Repatha Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Maximally tolerated statin not documented
- 2. LDL-C not at goal despite statin + ezetimibe
- 3. Statin intolerance not adequately documented (rechallenge trial missing)
- 4. ASCVD or FH diagnosis criteria not met
What to Include in a Repatha Letter of Medical Necessity
Document ASCVD history or FH diagnosis, current and prior lipid-lowering therapies with doses, LDL-C values on maximally tolerated statin plus ezetimibe, statin intolerance documentation with rechallenge if applicable, and FOURIER trial data supporting CV risk reduction in the patient's risk profile.
Key clinical evidence to cite:
- ✓ FOURIER cardiovascular outcomes trial
- ✓ OSLER-1 and OSLER-2 long-term extension
- ✓ RUTHERFORD-2 (HeFH)
- ✓ TESLA and TAUSSIG (HoFH)
Relevant guidelines:
- 📖 ACC/AHA 2018 Cholesterol Guidelines
- 📖 NLA PCSK9 Inhibitor Recommendations
- 📖 ESC/EAS 2019 Dyslipidemia Guidelines
Payers Covering Repatha
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Repatha Prior Authorization FAQ
Why was my Repatha prior authorization denied?
The most common denial reasons for Repatha are: Maximally tolerated statin not documented; LDL-C not at goal despite statin + ezetimibe; Statin intolerance not adequately documented (rechallenge trial missing); ASCVD or FH diagnosis criteria not met.
What should a Repatha Letter of Medical Necessity include?
Document ASCVD history or FH diagnosis, current and prior lipid-lowering therapies with doses, LDL-C values on maximally tolerated statin plus ezetimibe, statin intolerance documentation with rechallenge if applicable, and FOURIER trial data supporting CV risk reduction in the patient's risk profile.
Which payers cover Repatha?
Repatha is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part D, though formulary tier and prior authorization criteria vary.